Index	awareness, 504
IIIdeA	counteractivities, 603-605
	direct, <i>521–522</i>
A	gays and lesbians, 509
AARP See American Association of Retired Persons	indirect, 521
Abdomen, 310	power of, 497
Abdominal trauma, 281	restrictions, 515, 596–597
Abdominal acrtic aneurysm, 14	Advocacy, anti-tobacco, 634
Abortion, spontaneous, 14, 272, 281–283, 307, 370	programs, 600–606
abruptio placentae, 281	Advocacy Institute, 603
environmental tobacco smoke, 16, 364, 368, 372	Affect, 569
infertility, 273, 276	negative, 331, 482, 483
risk, 304	AFL-CIO, 602
Abruptio placentae, 14, 279–281, 307, 370	Africa, American man See Plack man
Abstinence, 581, 606; See also Smoking cessation	African American men See Black men African American women See Black women
lung cancer risk, 200	
menstrual cycle, 559–560	Age
Academic performance, 66, 472	assisted reproduction, 273 atherosclerosis, 241
Acculturation, 581–582	breast cancer risk, 212
ACS See American Cancer Society	•
Action on Smoking and Health, 603	chronic obstructive pulmonary disease preva- lence, 257
Addiction See Nicotine dependence	·
Adenocarcinoma, 201, 635	cigar use, 116
cervical cancer, 220	cigarette brand preference, 47 coronary heart disease, 232, 233, 369
diet and lung cancer, 208	gestational See Gestational age
esophageal cancer, 226	
incidence, 202	maternal See Maternal age
oropharyngeal cancers, 225	mortality risk, 184–186
urinary tract cancers, 228	pregnancy and smoking cessation, 484
Adenoma, colorectal, 226	smoking after pregnancy, 484
Adipose tissue, nicotine metabolism, 339	smoking cessation, 485–487, 386–387
Adolescents	smoking initiation, 74
body weight, 308	stages of smoking cessation, 110
depression, 134, 333–334	Age factors
dysmenorrhea, 561	older smokers, 554
lung growth, 370	smoking cessation, 553, 562
nicotine dependence, 334, 557	smoking cessation during pregnancy, 579
promotions and smoking initiation, 504	Aging, smoking cessation, 486–487, 562, 583–584
restrictive tobacco policies, 593, 606	Air pollution, 208, 261
smoking cessation, 572–573, 606	Airflow, expiratory, 249
smoking initiation, 63, 82, 453–477	Airflow obstruction, 249
smoking and lung development, 252, 261	Airline flights, 602
smoking prevalence, 142, 635	Alaska Native girls
tobacco advertisements, 511	physician advice about smoking, 115
tobacco marketing campaigns, 500–505	smokeless tobacco, 121
Adult Use of Tobacco Surveys, 23, 28, 29, 553	smoking prevalence, 61
cigar use, 116–117	Alaska Native women, 142
cigarette brand preference, 46	birth weight, 302
environmental tobacco smoke, 122	cigar use, 117
heavy smoking, 42	current smoking, 39
nicotine replacement therapy, 98, 99	environmental tobacco smoke, 123
	ever smoking, 33
physician advice about smoking, 112	heavy smokers, 43–44, 45, 46
pipe use, 118–119 smoking cossation, 96, 100, 106, 551	smokeless tobacco, 119
smoking cessation, 96, 100, 106, 551	smoking cessation, 100, 101, 578, 582
smoking continuum, 107, 108	smoking during pregnancy, 73
Adults, older, smoking cessation, 486–487, 562	smoking prevalence, 11, 37, 40–41, 48, 635
Advertising, 490–511; See Marketing	smoking prevention, 636

Alaska Native young women, current smoking, 49	American Stop Smoking Intervention Study, 589
Alcohol consumption, 129, 130, 484, 486	American Tobacco Company, 493, 494, 495, 510
binge drinking, 130	Amniotic fluid, 278
combined with tobacco, 224-225	Ampulla of Vater, 228
esophageal cancer, 226	Anal atresia, 306
laryngeal cancer, 225–226	Anaplastic thyroid cancer See Thyroid cancer
liver cancer, 227	Androgen, 217, 265, 311
oropharyngeal cancers, 224-225	Androstenedione, 265
ovarian cancer, 220	Anencephaly See Neural tube defects
pancreatic cancer, 228	Anger, 473
smoking cessation, 485	Ankle brachial pressure index, 245
smoking during pregnancy, 484	Antidepressants, 556, 557, 569–570
spontaneous abortion, 281	Antioxidants, cervical cancer, 223
Alcohol dependence, 16, 335, 336, 371	Antismoking campaign, effect on prevalence, 29
Alpha-tocopherol, 208	Antismoking materials, 523
Altitude, 281	Anxiety, 473
Alzheimer's disease, 16, 336–337, 372	Anxiety disorders, 16, 334–335, 336, 371
Amenorrhea, 266, 370	Anxiolytics, 556, 557
American Association of Retired Persons study, smoking	Aortic aneurysm, abdominal, 247, 248, 370
cessation attempts, 96	Aortic atherosclerosis, 247
American Cancer Society, 26, 184;See Cancer Prevention	Appetite, suppression, 475–476
Study I; Cancer Prevention Study II	
0	Arthritis, 15, 327–330, 371 Asbestos, 207
community intervention programs, 589	
American Cancer Society survey	Ascorbic acid, maternal levels, 278
ever smoking, 59	Asia
physician advice about smoking, 112, 115	oral cancers, 225
smoking cessation, 95	smokeless tobacco use, 138
American College of Chest Physicians, 601	smoking prevalence, 136
American College of Obstetricians and Gynecologists, 601	Asian or Pacific Islander girls
American Indian girls	physician advice about smoking, 115
current smoking, 59	smoking intensity, 62
physician advice about smoking, 115	smoking prevalence, 61
smokeless tobacco, 121	Asian or Pacific Islander women, 44, 46
smoking intensity, 62	current smoking, 39
smoking prevalence, 61	environmental tobacco smoke, 123
American Indian infants, sudden infant death syndrome,	ever smoking, 33
306	lung cancer incidence, 195
American Indian women See Also Canadian Indian	smokeless tobacco, 119
women; Cherokee tribe; Hopi women; Lumbee tribe	smoking cessation, 100, 583
cigar use, 117	smoking during pregnancy, 73
current smoking, 39	smoking prevalence, 11, 37, 41, 48, 142, 635
environmental tobacco smoke, 123	Asian or Pacific Islander young women
ever smoking, 33	current smoking, 49
heavy smokers, 43–44, 45, 46	smoking prevalence, 50
smokeless tobacco, 119	Association of Flight Attendants, 602
smoking cessation, 100, 101, 578, 582	Association of Professional Flight Attendants, 602
smoking cessation during pregnancy, 111	Asthma, 249, 252, 258
smoking during pregnancy, 73	Athens, Greece, air pollution and lung cancer risk, 209
smoking prevalence, 11, 37, 40–41, 48, 142, 635	Atherosclerosis See Carotid atherosclerosis
smoking prevention, 636	Atherosclerosis Risk in Communities Study, 243
American Indian Women's Health Education Resource	Athletics, 600
Center, 601	Atomic bomb survivors, lung cancer, 209
American Indian young women, current smoking, 49	Attention, 341, 560
American Lung Association, nicotine replacement therapy,	Attention, 341, 300 Attention deficit disorder, 15, 334–335, 336, 371
98, 99	Attitudes, 592, 594, 595
American Medical Women's Association, 601, 605	
American Nurses Association, 601	Attorneys General settlement See Master Settlement
	Agreement
American Public Health Association, 603, 605	

Australia chronic obstructive pulmonary disease mortality, 261 community-based antismoking campaigns, 588 lung cancer, 210–211 smoking trends, 138 Australian National Women's Magazine Project, 604 Austria, lung cancer mortality, 211 Auto racing, sponsorship, 514 Autopsy, 350 AUTS See Adult Use of Tobacco Surveys	preterm delivery, 291 Bisexual women, current smoking, 42 Bisexual youth, smoking prevalence, 59 Black adolescents emotional distress, 473 risk taking behavior, 472 smoking initiation, 470, 472 smoking prevalence, 635 Black boys, smoking prevalence, 61 Black children, maternal smoking and lung function, 251
В	Black girls cigarette brand preference, 70
Badge products, 492 Bailancho Saad, 526 Basic brand, advertising, 510 Beaver Dam (Wisconsin) Eye Study, 330 Behavioral control, smoking initiation among adolescents, 471	current smoking, 57, 58 ever smoking, 55, 59 physician advice about smoking, 115 smoking and body weight, 126 smoking intensity, 62–63 smoking prevalence, 7, 11–12, 57, 60, 61, 70, 142
Behavioral programs, 566–567, 570	weight control, 476
Behavioral Risk Factor Surveillance System, <i>23</i> , 40–41, 42, 72 Behavioral training, smoking cessation, <i>584</i>	Black infants, sudden infant death syndrome, 306 Black men chronic obstructive pulmonary disease mortality, 260
Benign breast disease, 217	ever smoking, 49
Benson & Hedges brand, 46, 47	lung cancer incidence, 194
advertising, 510, 521–522	smoking cessation, 106
international sponsorship, 523	smoking prevalence, 29
Benzo[a]pyrene, 207 Benzodiazepines, 556	Black women
Bernays, Edward, 494, 495	age at smoking initiation, 75, 76, 77, 80
Beta-blockers, 556	birth weight, 302
Beta-carotene, 208	body weight, 127
cervical cancer, 223	bone fractures, 311
Betelquid, 138	breastfeeding, 484
Bidis, 121, 147	chronic obstructive pulmonary disease mortality, 260
Bile ducts, 228	cigarette brand preference, 46
Biliary tract cancer, 228	coronary heart disease risk, 232
Billboards, 521	current smoking, 39
Binge drinking, 130, 472; See also Alcohol consumption	environmental tobacco smoke, 123
Biological factors, smoking initiation, 476-477	ever smoking, 33, 78
Biopsychosocial factors, 552, 606	first cigarette of the day, 83
smoking cessation, 17	forced expiratory volume impairment, 259
Birth cohort studies, 28–29	heavy smokers, 43, 45, 46
Birth cohorts, 74–77	lung cancer, 194, 197, 200
and ever smoking by age, 77–81	neonatal mortality, 294
forced expiratory volume, 253	nicotine dependence, 88
initiation, 142	physician advice about smoking, 113
lung cancer trends, 203 smoking cessation, 105, 553	preeclampsia risk, 288
9	pregnancy and smoking cessation, 483
smoking initiation, 74–77, 81, 499 smoking initiation and coronary heart disease, 233	relapse to smoking, 487
Birth defects, 290, 303	smokeless tobacco, 119
Birth outcomes, 290–306	smoking cessation, 97, 100, 101, 106, 578, 579–580
smoking cessation, 564	smoking cessation during pregnancy, 111, 563, 577, 579
Birth weight 15, 296, 302–303, 371;See also Intrauterine	smoking cessation programs, 580
growth retardation	smoking continuum, 107
environmental tobacco smoke, 357, 368, 372	smoking during pregnancy, 71, 72, 73 smoking prevalence, 11, 27, 28–29, 35, 48, 142
low See Low birth weight	stages of smoking cessation, 110

stillbirth, 291	Bronchitis, chronic, 249, 250
Black young women	Brown & Williamson, 506, 510, 511
current smoking, 49	Buccal mucosa, 225
ever smoking, 49	Bulgaria, lung cancer mortality, 210-211
smoking cessation, 110	Bulimia nervosa, 16, 334–335, 336, 371
smoking prevalence, 50	Bupropion, 556
Blacks, television and smoking cessation, 577	pharmacology, 557
Bladder cancer, 13, 228, 231, 369	smoking cessation, 565, 570
Blood pressure See Hypertension	weight control, 569
Blood vessel diseases, 232	Bureau of Indian Affairs, 56, 59
Body fat distribution, 15, 310–311, 371	Bus stops, advertising, 521
Body image, 125, 134	bus stops, advertising, ozr
Body mass index, 329, 565; See also Body weight	С
maternal, 291	C
Body weight, 15, 125–128, 134, 307–311, 371; See also Body	Cadmium, 318
mass index	neonatal mortality, 365
bone density, 315, 317	Caffeine, preterm delivery, 291
endometrial cancer, 217	Calcaneus, 312
maternal, 303	·
nicotine effects, 341	Calcitonin, 318
osteoarthritis, 329	Calcium, 315, 318
perceived, <i>126–128</i>	California, tobacco control programs, 636
smoking initiation, 125	California Department of Health Services, 603, 604
Bone density, 15, 311-318, 321, 371	California Environmental Protection Agency, lung
Bone fractures, 318–321	cancer and environmental tobacco smoke, 344
risk, 15, 321, 371	California Tobacco Survey, 587
Boredom, and smoking, 134	promotions and smoking initiation, 504
Bowling, James, 498	susceptibility to smoking, 475, 504
Boys	tobacco product advertising, 455
cigar use, 117	California Youth Tobacco Survey, smoking initiation,
current smoking prevalence, 60, 61	472
depression, 341	Camel brand, 46, 504
maternal smoking and lung function, 251	advertising, 494, 496–497, 509, 510
religion and smoking, 67	brand stretching, 522
restrictions to access, 595	preference among girls, 69, 70
senior class, 59	promotions, 510
smokeless tobacco, 121	Canada
smoking initiation, 500	chronic obstructive pulmonary disease mortality,
9	261
smoking prevalence, 142	lung cancer, 209–211
Brain, nicotine metabolism, 339	smoking trends, 138
Brand stretching, 522	Canadian Association for the Advancement of
BRCA1 genes, 216	Women and Sport and Physical Activity, 600
BRCA2 genes, 216	Canadian Indian women, smoking prevalence, 136
Breast cancer, 13, 212–217	Canadian Network of Women Against Tobacco, 605
correlations with male lung cancer, 216	Cancer, 12–13, 193–231; See also under individual type
environmental tobacco smoke, 216, 369	predisposition to, 205–207
risk, 213, 224, 369	
susceptibility, 634	Cancer Prevention Study I, 26, 28, 37, 42
Breast disease, benign, 217	age at smoking initiation, 75, 76
Breastfeeding, 15, 306, 307, 371, 484, 488	aortic aneurysm mortality risk, 247
relapse to smoking, 487	chronic obstructive pulmonary disease mortality,
smoking cessation, <i>484</i> , <i>577</i> , <i>579</i>	260
BRFSS See Behavioral Risk Factor Surveillance System	coronary heart disease, 353
Brief interventions See Clinical interventions, minimal	death rates, 186–187
Brill, A.A., 494	lung cancer risk, 197, 200
Bronchial hyperresponsiveness, 253	multiple myeloma, 231
Bronchiectasis, 249	stroke mortality risk in former smokers, 239
Bronchioles, 249	Cancer Prevention Study II, 42
Bronchioloavelolar regions, carcinogens, 203	age at smoking initiation, 75
υ , τος π, το	

biliary tract cancer, 228	Case-control studies
bladder cancer mortality, 229	breast cancer, 212
breast cancer and environmental tobacco smoke, 216	coronary heart disease and environmental tobacco
chronic obstructive pulmonary disease mortality, 260,	smoke, <i>353</i>
261	environmental tobacco smoke, 345-350
coronary heart disease, 223, 233, 353	ethnicity and lung cancer, 200
death rates, 185–187	lung cancer, 198–200
esophageal cancer, 226	CASH See Cancer and Steroid Hormone Study
	<u> </u>
laryngeal cancer, 226	Cataract, 15, 330, 331, 371
liver cancer mortality, 227	Catecholamines, 265
low-tar cigarette preference, 48	Cavalier brand, advertising, 497
lung cancer, 200, 201	Censorship, 524
lymphoid leukemias, 231	Centers for Disease Control and Prevention
multiple myeloma, 231	Office on Smoking and Health, 602
non-Hodgkin's lymphoma, <i>231</i>	public health partnerships, 600
pancreatic cancer mortality, 228	Central American women, smoking during
relative risk, 189–190	pregnancy, 73
risk and smoking cessation, 197–198	Central nervous system, congenital malformations,
smoking and breast cancer mortality, 215	303, 304
smoking risk in lung cancer, 197, 198	Cerebral infarction See Stroke
spouse exposure to environmental tobacco smoke,	Cerebrovascular disease See Stroke
344	Cervical cancer, 13, 220–224
stomach cancer, 226	risk, 224, 369
stroke risk, 240	
	smoking and disease progression, 220
Cancer and Steroid Hormone Study, 213	Cervical dysplasia, 220
ovarian study, 219–220	Cervical epithelium, effects of smoking, 223
Capri brand, 504, 508, 509	Cervical incompetence, 278
advertising restrictions, 525	Cervical intraepithelial neoplasia, 220
appeal to women, 522	Cesarean section, placenta previa, 281
promotions, 510	Cessation See Smoking cessation
Carbon monoxide, 303, 340, 341, 573	Change, transtheoretical model, 474, 478
congenital malformations, 304	Chelsea brand, 508
fetal growth retardation, 364	Cherokee tribe, See also American Indian women
neonatal mortality, 364	smokeless tobacco, 119
Carboxyhemoglobin, 303	Chesterfield brand, 46, 499, 500
Carcinogens, lung cancer, 203	advertising, 493, 494, 496, 498
Carcinoma, adenosquamous, cervical cancer, 220	Children
Carcinoma, bronchioloalyeolar, 201	cigarette advertising, 504
Carcinoma, large cell, 201, 208	coronary heart disease and environmental tobacco
<u> </u>	smoke, 353, 355
Carcinoma in situ, cervical, 220	
Carcinoma, small cell, 201, 202	environmental tobacco smoke, 345
diet and lung cancer, 208	forced expiratory volume, 251
Carcinoma, squamous cell, 201, 202, 203	nicotine dependence, 334
cervical cancer, 220	type 1 diabetes, 264
diet and lung cancer, 208	China, 136, 138
esophageal cancer, 226	air pollution and lung cancer risk, 208–209
Cardiac birth defects, 304	environmental tobacco smoke, 345
Cardiovascular defects, environmental tobacco	Chinese women, 41-42; See also Asian or Pacific Islander
smoke, <i>366</i>	women
Cardiovascular disease, 13–14, 232–238, 369	ethnicity and lung cancer, 200
environmental tobacco smoke, 122, 123	lung cancer, 195, 211–212
mortality, 187	smoking during pregnancy, 73
Cardiovascular function markers, 356	Chinese young women, smoking prevalence, 50
Caribbean Islands, smoking prevalence, 136	Cholecystectomy, 321
<del></del>	
Carlton brand, advertising, 509	Cholecystitis, 15, 323, 325, 371
Carotenoids, 208, 223	Cholelithiasis, 321, 323
Carotid artery stenosis, 241–242	Cholesterol, 232, 247
Carotid atheromatous plaques, 242	lung cancer risk, 208
Carotid atherosclerosis, 14, 241–244, 248, 370	

Chromosomal abnormalities, 281, 283, 303	lung cancer, 196–198
Chronic obstructive lung disease See Chronic	lung cancer and environmental tobacco smoke,
obstructive pulmonary disease	344–345
Chronic obstructive pulmonary disease, 14, 249–262,	mortality risk, 368
370	Colitis, ulcerative, 15, 325, 371
death rate, 250	College students, 67, 565
diagnosis, 249	Colon cancer, 225, 226–227
mortality, 259–261	Colorectal cancer, 13, 226-227, 231, 369
prevalence, 257	Commission for a Healthy New York, 602
risk, 250	COMMIT See Community Intervention Trial for Smoking
risk and smoking intensity, 261	Cessation
Cigar use, 116	Community, Hypertension, Atherosclerosis, and Diabetes
Cigarette addiction See Nicotine dependence	Program, 588
Cigarette advertisements, 490–511	Community Intervention Trial for Smoking Cesstion,
Cigarette brands	558
choices and advertising, 455	brand preference, 47, 70
images, 490	international programs, 588, 589
loyalty, 491	smoking after awakening, 83
preference, 46–48, 69–71	smoking cessation, 482–483, 574
Cigarette marketing See Marketing, 490–526	workplace policies, 587
Cigarette promotions See Promotions	Community-based interventions, 581, 587–590,
Cigarettes	598–599
brand stretching, 522	Compliance checks, 454
craving, 342	Conception, delayed, 14, 15, 272–273, 276, 307, 371
feminized, 522	environmental tobacco smoke, 16, 366, 368, 372
filtered, 47, 99, 203, 554	Condylomata, 224
first of the day, 82–85	Confidence, smoking cessation, 527
generic, 47, 70	Congenital malformations, 15, 303–306, 307, 371
low-tar, 47, 116, 203	environmental tobacco smoke, 366
low-yield, 302	Conotruncal malformations, 304
number smoked, 42, 482, 483; See also Smoking	Consolidated Cigar Corporation, marketing, 516
intensity	Contraception, spontaneous abortion, 281
packaging, 492–493, 522	Copenhagen City Heart Study, 241
price, 454–455, 510, 594	chronic obstructive pulmonary disease mortality,
reasons for use, 85–86	261
Cigars, 12, 116–117, 142	Coping skills, 474, 483
marketing, 516–517	Coronary Artery Surgery Study, 235
Cimetidine, 324	Coronary heart disease, 232–238, 369
Circulatory anomalies, 303	environmental tobacco smoke, 16, 343, 350–356,
Civic improvement, tobacco sponsorship, 511	372
Clear Horizons, 583, 584	hormone replacement therapy, 237–238
Clearing the Air, 584	mortality, 233, 356
Cleft lip See Oral clefts	risk, 13, 232–235, 248, 353
Cleft palate See Oral clefts	Coronary Risk Factor Study, 588
Clinical interventions, intensive, 555–556	Corpora lutea, 273
	•
pregnancy, 578 Clinical interventions, minimal, 554–555, 556	Cortisol, 217, 265, 318 Cotinine, 16, 83, 123, 372
pregnancy, 578	birth weight, 302, 357, 362
Cliques, smoking initiation among adolescents, 469	<u> </u>
	blood pressure, <i>248</i> in cervical mucus, <i>223</i>
Clomiphene citrate challenge, <i>273</i> Clonidine, <i>556</i> , <i>557</i>	fetal growth retardation, 364
	O Company of the comp
Cocaine use, 129, 130	infant lung development, 251
Conditive readiness, 488	levels during pregnancy, 563
Cohabitant See Partner	nicotine metabolism, 339
Cohort studies	preterm delivery, 291
breast cancer, 212	smoking intensity, 335
coronary heart disease and environmental tobacco	weight gain, 568
smoke, <i>351</i> , <i>353</i>	Counteradvertising, 603

Covariate studies, 315	Department of Defense Survey of Health Related
CPS-I See Cancer Prevention Study I	Behaviors Among Military Personnel, 39
CPS-II See Cancer Prevention Study II	Depression, 15, 333-334, 336, 371, 473, 557
Craniosynostosis, 304	adolescents, 476
Craven "A" brand, 519	major depressive disorder, 569, 570
Craving, cigarette, 342	premenstrual dysphoric disorder, 561
Crohn's disease, 15, 325, 371	smoking cessation, 486, 569–570, 571
Cross-sectional studies	smoking risk, 334
bone density, <i>313–315</i>	social support, 571
smoking initiation among adolescents, 454	Depression and smoking, 15, 130, 134
Crow's foot area, 332	Desogestrel, dose, 237
Cuban American women, 39, 45	Detroit, Michigan, environmental tobacco smoke
cigarette brand preference, 47	exposure, 347
smoking during pregnancy, 73	Developed countries, 519
Cultural influences, 453	deaths from smoking, 190
Current Population Survey, 23, 26, 46	lung cancer trends, $209-211$
age at smoking initiation, 75	smoking behavior, 135
cigar use, 117	Developing countries
smoking cessation, 101	lung cancer mortality, 211–212
smoking initiation, 74, 80, 81, 82, 499	marketing, 520
smoking intensity, 44, 74	smoking behavior, 135
smoking prevalence, 26, 42	smoking prevention, 637
trends in smoking cessation, 100	DHEAS, pregnant smokers, 262
workplace tobacco smoke exposure, 123	Diabetes mellitus
<i>CYP1A1</i> genes, <i>216</i>	14, 264, 370; See also Gestational diabetes
Cystic fibrosis, 249	preeclampsia, 288
Czech Republic, smoking prevalence, 136	smoking intensity, 264
1 / 01	Diagnostic and Statistical Manual of Mental Disorders,
	82, 86, 334–335, 561
D	
D	Diet, lung cancer, 208
$\mathrm{D}_2$ dopamine receptors, 476	
${\rm D}_2$ dopamine receptors, 476 d-Fenfluramine, weight control, 568–569	Diet, lung cancer, 208  Dieting, 125, 565  Diffusion of innovations model, 471
${\rm D}_2$ dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand	Diet, lung cancer, 208  Dieting, 125, 565  Diffusion of innovations model, 471  Digestive malformations, 305–306
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511	Diet, lung cancer, 208  Dieting, 125, 565  Diffusion of innovations model, 471  Digestive malformations, 305–306  Disease outcomes, 634, 636
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371 abruptio placentae, 281	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333 emphysema, 250
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333 emphysema, 250 limb reductions, 305
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371 abruptio placentae, 281 Demand for cigarettes, pricing, 455 Denmark	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333 emphysema, 250 limb reductions, 305 low birth weight, 302
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371 abruptio placentae, 281 Demand for cigarettes, pricing, 455 Denmark cigar use, 138	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333 emphysema, 250 limb reductions, 305 low birth weight, 302 lung cancer, 197
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371 abruptio placentae, 281 Demand for cigarettes, pricing, 455 Denmark cigar use, 138 human papillomavirus infection, 223	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333 emphysema, 250 limb reductions, 305 low birth weight, 302 lung cancer, 197 menopause, 269
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371 abruptio placentae, 281 Demand for cigarettes, pricing, 455 Denmark cigar use, 138 human papillomavirus infection, 223 lung cancer, 210–211	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333 emphysema, 250 limb reductions, 305 low birth weight, 302 lung cancer, 197 menopause, 269 neonatal mortality, 295
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371 abruptio placentae, 281 Demand for cigarettes, pricing, 455 Denmark cigar use, 138 human papillomavirus infection, 223 lung cancer, 210–211 smoking prevalence, 136	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333 emphysema, 250 limb reductions, 305 low birth weight, 302 lung cancer, 197 menopause, 269 neonatal mortality, 295 paternal smoking and congenital malformations,
D <sub>2</sub> dopamine receptors, 476 d-Fenfluramine, weight control, 568–569 Dakota brand advertising, 511 counteradvertising, 603 Dakota Papers, 603 Death, premature, 12 Death rate See also Mortality, 184–187 lung cancer, 197 smoking-specific, 184–186 temporal trends, 186–189 Deaths, smoking attributable, 190 Deaths, premature, 7, 194, 468 Decision making, 478 Dehydroepiandrosterone, 262 Delinquency, smoking initiation among adolescents, 472 Delivery, preterm, 15, 278, 290–291, 307, 371 abruptio placentae, 281 Demand for cigarettes, pricing, 455 Denmark cigar use, 138 human papillomavirus infection, 223 lung cancer, 210–211	Diet, lung cancer, 208 Dieting, 125, 565 Diffusion of innovations model, 471 Digestive malformations, 305–306 Disease outcomes, 634, 636 Displays, point-of-sale, 521 Distal influences, 453 District of Columbia Interagency Council on Smoking and Health, 604 DNAdamage, human papillomavirus infection, 223 Doctors Ought to Care, 604 Dopamine transporter gene, 476 Doral brand, advertising, 510 Dose-response relationship See also Smoking intensity carcinoma, 202 carotid atherosclerosis, 241 coronary heart disease and environmental tobacco smoke, 353 depression, 333 emphysema, 250 limb reductions, 305 low birth weight, 302 lung cancer, 197 menopause, 269 neonatal mortality, 295

smoking intensity and stroke, 240	smoking cessation, 527
spontaneous abortion, 281–283	Employment status, smoking cessation, 101, 102
stomach cancer, 226	Encephalocele See Neural tube defects
sudden infant death syndrome, 307	Endometrial cancer, 13, 217-218, 369
tar and lung cancer, 200	risk, <i>224</i>
urinary tract cancers, 229	Endometrial hyperplasia, 218
urinary tract malformations, 305	Endometriosis, 269–271
Down syndrome, 305	England, lung cancer, 210
DRD4 gene, 334	Entertainment, sponsorship, 492
Drug use	Environmental exposure See Environmental tobacco smok
intravenous, abruptio placentae, 281	Environmental factors, smoking initiation, 454–470
smoking, 129–130, 134	Environmental Protection Agency, lung carcinogens, 344
smoking initiation, 130	Environmental tobacco smoke, 7, 14, 122–125, 343–368,
DSM See Diagnostic and Statistical Manual of Mental	487, 592–593, 636
Disorders	breast cancer, 13, 216, 224, 369
Dual photon absorptiometry, 312	cervical cancer, 224
Dual X-ray absorptiometry, 312	childhood lung function, 14
Duodenal ulcer See Peptic ulcer	children, 251–252, 345
Duodenum, 324	conception delay, 368
Dysmenorrhea, 14, 266, 272, 370, 561	coronary heart disease, 16, 350–356, 372
	developing countries, 637
_	exposure indicators, 345
E	exposure levels, 345
Eastern Europe ampling providence 196	home exposure, 122–123
Eastern Europe, smoking prevalence, 136	infant pulmonary function, 250
Eclampsia, 283, 288	lung cancer, 16, 372
Ectopic pregnancy, 14	lung development, 250, 370
Edema, 283	maternal exposure and neonatal mortality, 364-365
Edinburgh Artery Study, 245	perinatal effects, 357–366
Education	reproductive outcomes, 16, 356–358, 372
plans after graduation, 66, 71	smoking cessation, 484
tobacco control advocacy programs, 601-602	sudden infant death syndrome, 306
Education level, 575–576	in utero exposure, 217, 261
current smoking, 48	workplace, 123–125, 350
environmental tobacco smoke, 123	Esophageal cancer, 13, 226, 231, 369
ever smoking, 33	Essence (magazine), 604
heavy smoking, 46	Established Populations for Epidemiologic Studies of
maternal smoking, 73	the Elderly, 223, 486
parental, 64	
physician advice about smoking, 113	Estradiol, 262
pregnancy and smoking cessation, 484, 577, 579	breast cancer risk, 212
smoking after pregnancy, 484	cancer, 217
smoking bans, 123	infertility, 273
smoking cessation, 101, 110, 483, 486, 488, 527	Estriol, 217
smoking cessation during pregnancy, 111	Estrogen, 212, 230; See also Hormone replacement therapy
smoking prevalence, 11, 37, 42, 142	bone density, 315
smoking prevalence, 11, 37, 42, 142 smoking prevalence among young women, 50,	dose and stroke risk, 241
50-51	endometrial cancer, 218
	excretion, 262
stages of smoking cessation, 110	exogenous See Hormone replacement therapy
television and smoking cessation, 577	metabolism, 262, 370
workplace exposure, 124	oral, 237
Embassy brand, 519	Estrogen replacement therapy See Hormone replacement
Emotions, 134, 473	therapy
Emphysema, 249; See also Chronic obstructive pulmonary	Estrogen-deficiency disorders, 14, 265, 370
disease	Estrogen-dependent disorders, 14, 265, 270, 370
Emphysema Slims tennis tournaments, 604	Estrogen-receptor tumors, 213–214
Employment	Estrogens, 14
pregnancy, 288	Estrone, 212, 262

Ethinyl estradiol, 562	environmental tobacco smoke, 357, 364–365
dose, 236, 237	Fetal malpresentation, placenta previa, 281
Ethnicity	Fetal morbidity and mortality See Neonatal
age at smoking initiation, 76	morbidity; Neonatal mortality
cigarette brand preference, 70	Fetal nutrition, 303
lung cancer, 200	Fetuses, multiple, 288
smoking prevalence during pregnancy, 73	FEV See Forced expiratory volume
Europe	Fibroadenoma, 217
environmental tobacco smoke exposure, 348	Fibrocystic disease, 217
esophageal cancer incidence, 226	Fighting, 472
lung cancer rates, 210	Filipino women See also Asian or Pacific Islander
smoking prevalence, 136	women
European Union 1998 Directive, advertising restrictions,	lung cancer, 195, 200
525	smoking during pregnancy, 73
Eve brand, <i>506</i>	Filipino young women, smoking prevalence, 50
product placement, 523	Film, <i>521</i>
Ever smoked, 142	Finland
by age, 77–81	lung cancer, <i>210–211</i>
breast cancer risk, 216	smoking trends, 138
trends, 29–34	Flair brand, 506
young women, 48	Flight attendant associations, 602
Exercise, 315	Flight Attendant Non-Smokers, 602
smoking cessation, 584	Florida, environmental tobacco smoke, 345
Exercise programs, 567	Fluoxetine hydrochloride, weight control, 568
Experimental smoking, 474	Folic acid, 303
Expiratory flow rates, 251	Follicular atresia, 269
Extroversion, smoking cessation, 482	Follicular fluid, 273
Eye disease, 15, 330–331, 371	Follicular phase
	smoking cessation, 560
	withdrawal symptoms, 559
F	Follicular thyroid cancer See Thyroid cancer
F 11 111 . 17 000 071	Forced expiratory volume, 249, 252, 253
Facial wrinkling, 15, 332, 371	smoking cessation, 253, 257
	8 , ,
Fagerström Tolerance Questionnaire, 574	Forced vital capacity, 249, 252
Fallopian tubes, 273, 276	Forced vital capacity, 249, 252 Forearm, 312
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer;	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer;	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368 smoking cessation, 552	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France lung cancer, 209, 210–211
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368 smoking cessation, 552 Fertilization rates, 273	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France lung cancer, 209, 210–211 smoking prevalence, 136
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368 smoking cessation, 552 Fertilization rates, 273 Fertilization, in vitro, 273	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France lung cancer, 209, 210–211 smoking prevalence, 136 smoking trends, 138
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368 smoking cessation, 552 Fertilization rates, 273 Fertilization, in vitro, 273 Fetal growth, 303, 357	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France lung cancer, 209, 210–211 smoking prevalence, 136 smoking trends, 138 Freedom from Smoking for You and Your Family, 566
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368 smoking cessation, 552 Fertilization rates, 273 Fetilization, in vitro, 273 Fetal growth, 303, 357 Fetal hypoxia, 303	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France lung cancer, 209, 210–211 smoking prevalence, 136 smoking trends, 138 Freedom from Smoking for You and Your Family, 566 Friends See Peers
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368 smoking cessation, 552 Fertilization rates, 273 Fertilization, in vitro, 273 Fetal growth, 303, 357 Fetal hypoxia, 303 congenital malformations, 304	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France lung cancer, 209, 210–211 smoking prevalence, 136 smoking trends, 138 Freedom from Smoking for You and Your Family, 566 Friends See Peers Frontier Menthol Slims brand, advertising restrictions, 525
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368 smoking cessation, 552 Fertilization rates, 273 Fettilization, in vitro, 273 Fetal growth, 303, 357 Fetal hypoxia, 303 congenital malformations, 304 nicotine, 364	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France lung cancer, 209, 210–211 smoking prevalence, 136 smoking trends, 138 Freedom from Smoking for You and Your Family, 566 Friends See Peers
Fallopian tubes, 273, 276 Family conflict, smoking initiation, 455, 468 Family history, 205–207 Fashion, cigarette advertising, 497 Fat, dietary, lung cancer risk, 208 Fat distribution See Body fat distribution Fatalism, smoking initiation among adolescents, 471–472 Fecundity, environmental tobacco smoke, 366–368 Federation Internationale de Football Association (FIFA), 600 Female cancers, 13, 212–224, 369; See also Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvar cancer Fertility environmental tobacco smoke, 366–368 smoking cessation, 552 Fertilization rates, 273 Fettlization, in vitro, 273 Fetal growth, 303, 357 Fetal hypoxia, 303 congenital malformations, 304	Forced vital capacity, 249, 252 Forearm, 312 Fortuna brand, brand stretching, 522 Fortune Magazine survey, 23, 26 Four A's protocol, 579–580 Framework Convention for Tobacco Control, 637 Framingham Study, 26 bone density, 315 carotid atherosclerosis, 241 gallbladder disease, 323 menopause, 268 osteoarthritis, 329 peripheral vascular disease risk, 245 smoking cessation, 103 type 2 diabetes, 264 France lung cancer, 209, 210–211 smoking prevalence, 136 smoking trends, 138 Freedom from Smoking for You and Your Family, 566 Friends See Peers Frontier Menthol Slims brand, advertising restrictions, 525

G	Gender susceptibility, lung cancer, 201
Callbladdon 990	Genetic polymorphisms, breast cancer risk, 216
Gallbladder, 228 Gallbladder disease, 321–324, 325, 371	Genetic predisposition, lung cancer, 205
	Genetics, 476
Gallstones, <i>15</i> , <i>321</i> , <i>325</i> , <i>371</i> Gallup Poll, <i>26</i>	Mendelian inheritance, 206
Gamete interaction, 273	psychiatric disorders, 336
	Genital warts, 224
Gastric mucosa, 324	Genitourinary defects, environmental tobacco
Gastric ulcer See Peptic ulcer	smoke, <i>366</i>
Gastrointestinal abnormalities, 303, 305–306	Germany
Gastrointestinal diseases, 15, 321–327, 371	environmental tobacco smoke exposure, 349
Gastroschisis, 306	lung cancer mortality, 210–211
Gauloises Blondes brand, direct advertising, 521	Gestational age, 290
Gay men	birth weight and environmental tobacco smoke,
HIV disease, 331	357
targeted advertising, 509	preterm delivery, 291
Gender	Gestational age, small, 15, 290, 296, 303, 307, 370
acculturation, 581–582	Gestational diabetes, 14, 265, 370; See also Diabetes
adolescent smoking, 66	mellitus
Alzheimer's disease, 337	Gestational hypertension, 283
attitudes towards smoking, 475	Gestodene, dose, 237
chronic obstructive pulmonary disease, 249, 250	Gingival recession, 116
cigarette advertising, 509	Girl Scouts of the USA, 601
depression, 371	Girls, See also under entries at Alaska Native, American
depression and adolescents, 333, 334	Indian, Asian or Pacific Islander, Black, Hispanic, Latin
dieting among college students, 565	American, Mexican American, Navajo, and White
esophageal cancer incidence, 226	attitudes about smoking, 67–69
first cigarette of the day, 83	cigar use, 117
inflammatory bowel disease, 325	cigarette brand preference, 69–71
intensive clinical interventions, 555–556	cigarette smoking, 52–70
laryngeal cancer, 225	current or ever smoking, 59
lung cancer, 201, 203, 209	current smoking, 56–61, 59–61
lung function, 253	depression, 333
nicotine dependence, 88, 91, 142, 342	emotions and smoking, 134
nicotine intake, 372	ever smoking, 54, 55
nicotine pharmacology, 339, 476	first cigarette of the day, 83–85
nicotine replacement therapy, 556	lung function, 261, 370
physician advice about smoking, 112	lung growth, 14
reasons to quit smoking, 572	nicotine dependence, 82, 88
relapse to smoking, 107	other drug use, 129–131, 134
restrictions on youth access, 595	<del>-</del>
risk for urinary tract cancers, 228	physician advice about smoking, 115
schizophrenia, 335	pregnant, 71–73, 111
smokeless tobacco, 120	psychosocial problems and smoking, 134
smoking cessation, 102–106, 482, 483, 550–552	reasons for cigarette use, 86 restrictions to access, 595
smoking cessation among adolescents, 111	
smoking cessation among older smokers, 583–584	senior class, 59–61
smoking cessation methods, 553, 554, 588, 606	smokeless tobacco, 121
smoking and disease outcomes, 634	smoking cessation, 17, 111, 115
smoking initiation among adolescents, 454	smoking initiation, 16, 500, 527
smoking prevalence, 11–12, 142	smoking intensity, 62–63, 70, 82
social support, 571–572	smoking and lung function, 14
	smoking prevalence, 7, 11–12, 70, 142
stages of smoking cessation, 110	weight, 125–126, 527
taxation policies, 594	Girls Incorporated of Alameda County, 601
television and smoking cessation, 576	Girls organizations, tobacco control advocacy
tobacco-related policies, 591–592	programs, 601
in utero lung development, 251	Glaucoma, 15, 331, 371
weight gain, <i>565</i>	Glucose regulation, 14, 265, 370

Glucose tolerance, 265	Hip fracture, 15, 371
Goiter, 230, 263	mortality, 311
Golden Handcuffs Challenge, 604	risk, 318–319, 321
Golden Tobacco Company, targeting women, 526	Hispanic adolescents, risk taking behavior, 472
Gonadotropins, 269, 273	Hispanic girls
Graves' disease, 263	cigarette brand preference, 70
with ophthalmopathy, 263, 265, 370	current smoking, 56
Graves' ophthalmopathy, 14	ever try smoking, 55, 56
Great Britain See United Kingdom	physician advice about smoking, 115
Greece	smoking and body weight, 126
air pollution and lung cancer risk, 209	smoking intensity, $62-63$
lung cancer mortality, 210–211	smoking prevalence, 61
smoking prevalence, 136	Hispanic Health and Nutrition Examination Survey, 229
smoking trends, 138	cigarette preference, 47
GSTM1 genes, 216	environmental tobacco smoke, 122
Gudakhu, 138	smoking prevalence, 39
Gynecologic conditions, benign, 14, 266–272, 370	Hispanic men
	smoking cessation, 106
Н	smoking prevalence, 29
	Hispanic women
Harbin, China, environmental tobacco smoke expo	age at smoking initiation, 77, 80
sure, 345	body weight, 127
Harvard Six Cities Study, air pollution and chronic	cigarette preference, 47
obstructive pulmonary disease, 261	current smoking, 39
Hawaiian women <i>See also</i> Asian or Pacific Islander	environmental tobacco smoke, 122, 123
women	ever smoking, 33
lung cancer, 195, 200	heavy smokers, 45, 46
smoking during pregnancy, 73	lung cancer, 195, 200
Health consequences of smoking, 12, 475, 633, 635	nicotine dependence, 88
Health consequences of smoking for women, 549	physician advice about smoking, 113
Health motives, smoking cessation, 550	smokeless tobacco, 119
Health Promotion and Disease Prevention Supple-	smoking cessation, 97, 100, 101, 106, 578, 581-582
ment, 553	smoking continuum, 107
Health promotion strategies, 17	smoking during pregnancy, 71, 73
Health Resources and Services Administration, Maternal	smoking prevalence, 11, 27, 28–29, 37, 48, 71, 142, 635
and Child Health Bureau, 602	Hispanic young men, ever smoking, 49
Healthy Worker Project, 586	Hispanic young women
Heart, nicotine metabolism, 339	current smoking, 49
Heart defects, 304	ever smoking, 49
conotruncal, environmental tobacco smoke, 366	smoking cessation, 110
Heart disease See Cardiovascular disease	smoking prevalence, 50
Heel, 312	HIV-1 infection, 15
Helicobacter pylori, 325	HMO study, lung cancer risk, 201
Hematologic cancers, 13, 231, 369	Hodgkin's disease, mortality, 231
Hemoglobin, fetal growth retardation, 364	Home exposure
Hemoglobin A <sub>1c</sub> , 265	environmental tobacco smoke, 122-123, 353
Hemorrhage	smoking bans, 123
intracerebral, 240	Homosexual men
postpartum, 281	HIV-1 disease, 331
Hepatitis B infection, liver cancer, 227	targeted advertising, 509
Hepatocellular carcinoma, 227	Hopelessness, 473
Herstories, 602	Hopi women See also American Indian women
HHANES See Hispanic Health and Nutrition	smoking prevalence, 40
Examination Survey	Hormone replacement therapy, 15, 217, 218; See also
High school drop outs, 66	Estrogen
Hill, George Washington, 493	breast cancer risk, 213
Hip, 312	coronary heart disease, 237–238, 369
osteoarthritis, 329	ovarian cancer, 220

sex hormones, 262	Inhalant use, 130
smoking cessation, 562	Initiation See Smoking initiation
stroke, 241, 248, 370	Initiatives to Mobilize for the Prevention and
stroke risk, 14	Control of Tobacco Use, 589
thyroid cancer risk, 230	Insulin, 265
Hormones, smoking cessation, 558	Integumental anomalies, 303
Hostility, 473	Intelligence, smoking initiation among adolescents,
Household structure, 71	472
and smoking, 63	Intention to smoke, 474
HPV See Human papillomavirus infection	Intermittent claudication, 244
Human chorionic gonadotropin hormone, 281	International Classification of Diseases, ninth revision, 249
Human immunodeficiency virus, 15, 331, 371	International Conference on Tobacco and Health, 605
Human papillomavirus infection, 13, 223, 369	International Conference on Women and Smoking, 605
cervical cancer, 220	International Network of Women Against Tobacco,
vulvar cancer, 224	526, 602, 605
Humerus, fractures, 319	International Union Against Cancer, 605
Hungary, lung cancer, 210–211	Internet marketing, 516
25-Hydroxy vitamin D <sub>3</sub> , 318	Interventions
2-Hydroxyestradiol, 262	brief See Clinical interventions, minimal
2-Hydroxyestrones, 217	population-based, 558
Hyperinsulinemia, 265	Intracerebral hemorrhage, 369
Hypertension, 232, 240, 247–248	Intrauterine devices, 277
abruptio placentae, 281	Intrauterine growth retardation, 16, 290, 362–364, 372, 564
pregnancy, 283, 288–290	environmental tobacco smoke, 368
Hyperthyroidism, 263	INWAT See International Network of Women Against
Hypothalamic-pituitary axis, effects of smoking, 561	Tobacco Iowa Women's Health Study, pancreatic cancer mortality,
Hypothyroidism, <i>263</i> Hysterectomy, <i>269</i>	228
Trysterectomy, 209	Ireland, <i>See also</i> United Kingdom
	lung cancer, 210–211
I	pancreatic cancer, 228
1	smoking trends, 138
Image, 475	Irritability, 473, 551
Imipramine hydrochloride, 569	Ischemic heart disease, fatal, 240
Immunosuppression, human papillomavirus, 220	Ischemic stroke See Stroke
IMPACT, 589	Italy
Implantation rates, 273	esophageal cancer, 226
Income	lung cancer, 211
adolescent personal, 66	smoking prevalence, 136
family, 64	smoming provincince, rec
smoking prevalence, 42	
Income level, 71; See also Poverty	J
self-help programs, 554	<u> </u>
smoking cessation, 101, 563, 579	Japan
smoking prevalence, 38	biliary tract cancer, 228
television and smoking cessation, 577	bladder cancer, 229
Income status, ever smoking, 33	lung cancer, 211
India	pancreatic cancer, 228
community-based interventions, 589	smoking prevalence, 136
oral cancers, 225	smoking trends, 138
smokeless tobacco use, 139	Japan Tobacco International, 523
Indian Health Clinics, smoking cessation project, 582	Japanese men, arsenic in drinking water, 208
Indoor air laws, 592	Japanese women, See also Asian or Pacific Islander
cigarette demand, 455	women
Industrialized countries See Developed countries	arsenic in drinking water, 208
Infection, during pregnancy, 278	lung cancer, 195
Infertility, 14, 15, 273–276, 307, 370, 371	pregnancy, 73
endometrial cancer, 217	smoking prevalence, 41–42
Inflammatory bowel disease, 325	Japanese young women, smoking prevalence, 50

Jasira Warriors, 601	smoking prevalence, 136
JCAHO See Joint Commission on the Accreditation	Latin American girls
of Health Care Organizations	smoking intensity, 62
Job stress, 486	smoking prevalence, 61
smoking after pregnancy, 484	Latin American Women Association on Smoking
Joe Camel, 500, 510	Control, 605
recognition among children, 504	Learning, nicotine effects, 341
Joint Commission on the Accreditation of Health Care	Leiomyomas See Uterine fibroids, 271
Organizations, 592	Leisure World Cohort Study, 233 Lesbian women
Josephine Camel, 510	current smoking, 42, 51
	S S S S S S S S S S S S S S S S S S S
T/	smoking prevalence, 59, 635, 636
K	targeted advertising, 509
Kaiser Permanente Medical Care Program cohort study, 188–189, 261	Leukemia, acute myeloid, 13, 231, 369 Leukoplakia, 116
Kaiser Permanente Medical Health Care Program Study,	Life expectancy, 368
lung cancer risk, 197, 198	U.S. women and smoking, 193
Kent brand	Life Skills Training Project, 598
advertising, 498	Liggett & Myers, 494, 498, 506
brand stretching, 522	product placement, 523
Khaini, 138	Lilith Fair concerts, 603
KICKIT!, 580	Limb-reduction defects, 305
Kidney, nicotine metabolism, 339	environmental tobacco smoke, 366
Kidney cancer, 13, 231, 369	Linked Telephone Survey, smoking cessation during
mortality, 229	pregnancy, 111
Kidney malformations, 305	Lipid Research Clinics Follow-up Study, coronary heart
Kim brand	disease, <i>232</i> Lipoprotein lipase, <i>311</i>
appeal to women, 522	Liver, nicotine metabolism, 339
sponsorship, 511	Liver, income metabolism, 339 Liver cancer, 13, 227–228, 231, 369
Knee, osteoarthritis, 329	Locus of control, smoking initiation among adolescents,
Kobe Declaration, 637	471–472
Kool brand, 46, 47, 504	Loneliness, and smoking, 134
sponsorships, 511	Longitudinal studies, 315
Korea	Lorillard, 506, 508
smoking prevalence, 136	sponsorship, 511
smoking trends, 138	Low birth weight, 15, 290, 296, 362–364, 371, 564
Korean women See also Asian or Pacific Islander women	environmental tobacco smoke, 362–364
lung cancer, 195	smoking cessation, 564
smoking prevalence, 41	Lucky Strike brand, 46, 499, 500
Korean young women, smoking prevalence, 50	advertising, 493, 494, 495
Kreteks, 116, 122, 148	Lumbee tribe, See also American Indian women
Kreyberg type II carcinoma See Carcinoma,	smokeless tobacco, 119
bronchioloalveolar	smoking cessation, 582
<b>.</b>	Lung, nicotine pharmacology, 339
<u>L</u>	Lung cancer, 7, 13, 193-212, 369; See also Adenocar-
L&M brand	cinoma; Carcinoma, large cell; Carcinoma, small
advertising, 497, 498	cell; Carcinoma, squamous cell
appeal to women, 522	differences by gender, 200–201
Lactation, 306	environmental tobacco smoke, 16, 122, 123, 207,
Langerhans' cells, 223	343–350, 372
Lark brand	epidemiologic studies, 344–350
advertising, 498	gender, 194, 209
product placement, 523	genetic predisposition, 205–207
Laryngeal cancer, 13, 225–226, 231, 369	international trends, <i>13</i> , <i>209–212</i> , <i>369</i>
Lasker, A.D., 494	mortality See Lung cancer mortality
Latin America	survival rates, 195
smoking and cervical cancer, 223	Lung cancer histology, dose-response rate relative risk, 202

Lung cancer mortality, 197, 209–211, 369 age-standardized rates, 211 developing countries, 211–212 international, 212	Massachusetts Tobacco Survey, 587, 594 Master Settlement Agreement, 515–516, 597 Maternal age abruptio placentae, 281
in men, 211  Lung cancer risk, 196–205, 209 case-control studies, 198–200 duration of smoking, 198 nonsmokers and environmental tobacco smoke, 343 risk factors, 207–209	birth weight, 302 congenital malformations, 303 placenta previa, 281 preterm delivery, 290 stillbirth, 291 Maternal and Child Health Block Grant programs,
Lung function, 14, 250–257, 370 decline in, 252 smoking cessation, 14	602 Maternal and Child Health Bureau, Health Resources and Services Administration, 602
in utero exposure to maternal smoking, 261 Lung Health Study, 253, 555, 575, 583 smoking cessation among heavy smokers, 575 weight gain, 309–310	Maternal smoking birth outcomes, 290–306 childhood lung function, 251–252 diabetes in children, 264
Lung parenchyma, 249 Lupus See Systemic lupus erythematosus Luteal phase smoking cessation, 560	infant lung function, 14, 261 smoking cessation, 551 smoking initiation among adolescents, 468–469 sudden infant death syndrome, 306
withdrawal symptoms, 559 Lymphoma, non-Hodgkin's, 231 Lymphoproliferative cancers, 13, 231, 369	in utero lung development, <i>250–251</i> , <i>370</i> Maudsley Personality Inventory, <i>482</i> Mecamylamine, <i>556</i> , <i>557</i>
M	Media advertising, 521 self-censorship, 517–519
Macroalbuminuria, 264	tobacco advertising, <i>527</i> Media censorship, <i>524</i>
Macular degeneration, 15, 330-331, 371	Medullary thyroid cancer See Thyroid cancer
Magazines	Membrane rupture, premature, 20
advertising, 505–510, 517–519, 521 counteradvertising, 603–604	Membranes, preterm premature rupture, 278–279, 307, 370, 371
Major depressive disorder See Depression Mania, 131	Memory, nicotine effects, 341 Memphis Health Project, 454
Manitoba Health Services Commission, 258	Men, See also under Asian Pacific Islander, Black,
Maori women See also Asian or Pacific Islander women	Hispanic, and White body weight, 127
smoking prevalence, 136	bone density, 315
Marijuana, 129, 130, 472	cigar use, 117
Marital status, smoking after pregnancy, 485	diabetes risk, 265
Marketing, 490–521; See also Advertising	gallstone, 321
international, 519–526	HIV-1 infection, 331
restrictions, 515, 524–525, 596–597 targeting of women, 526, 527 strategies, 520–524	international lung cancer mortality, 211 lung cancer, 201, 216, 343, 369
Marlboro brand, 46, 47, 500, 504	nicotine, 339
advertising, 493, 510–511	nicotine nasal spray, 340 physician advice about smoking, 112–113
brand stretching, 522	smoking cessation, 102–106, 486
international advertising, 520	vertebral fractures, 319
international sponsorship, 523	Menopausal hormones See Hormone replacement
nitrosamine content, 205	therapy
preference among girls, 69, 70	Menopause, 14, 268–269, 272, 370, 371
product placement, 523	bone density, 315
promotions, 510	hormone replacement therapy, 262
sponsorship, 511, 514	perimenopausal symptoms, 561
Mass media	smoking cessation, 552, 562
counteradvertising, 603 smoking cessation, 576–577	Menopause status benign breast disease, 217

bone density, 313–314	Miscarriage See Abortion, spontaneous
breast cancer, 213, 216	Mishri, 138
endometrial cancer, 217, 224	Misty brand
hormone levels, 262	advertising, 509
ovarian cancer, 220	promotions, 510
sex hormones, 262	Mobilization, tobacco control advocacy programs, 601-602
vertebral fractures, 319	Molecular genetics, depression, 334
Menses, 560	Monitoring the Future Surveys, 23, 52, 54, 57
Menstrual cycle, 552	academic performance, 66
irregularity, 266, 269, 370	attitudes about smoking, 67, 68
nicotine, 558, 559	cigarette brand preference, 69, 70
smoking cessation, 558–561	current smoking among girls, 58
withdrawal and abstinence, 559-560	current smoking prevalence, 60, 61
Menstrual disorders, smoking and endometrial	daily smoking, 60
cancer, 217	household structure, 63
Menstrual function, 14, 266–268, 272, 370	other drug use, 130
Mental health, and smoking, 131–135	parental education and smoking initiation, 471
Mental illness, smoking prevalence, 333	personal income, 66
Merit brand, advertising, 509	religion, 66
Meta-analyses	smokeless tobacco, 121
coronary heart disease studies, 356	smoking cessation, 95, 111
lung cancer and environmental tobacco smoke, 344	Mood, 135
Methacholine, 253	adolescents, 476
Methodologic issues, smoking studies, 52	dysphoric, 333
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, 204	menstrual cycle, 560
Mexican American girls, smoking intensity, 62	negative, 473
Mexican American women	nicotine, 341
age at smoking initiation, 77	Mood disorders, behavioral interventions, 570
birth weight, 302	Morbidity
body mass index, 128	coronary heart disease, 356
cigarette brand preference, 47	fetal, 290
environmental tobacco smoke, 122	neonatal, 290
ever smoking, 33	More brand, 506
heavy smokers, 45	appeal to women, 522
pregnancy, 73	sponsorship, 511
smoking prevalence, 29, 39	Mormon women, cervical cancer, 223
Mexican Americans, smoking cessation, 106	Mortality, 12, 13, 183-193, 368; See also Death rate;
Mexican girls, smoking prevalence, 61	Neonatal mortality; Perinatal mortality
Microalbuminuria, 264	Alzheimer's disease, 338
Middle East, smoking prevalence, 136	chronic obstructive pulmonary disease, 14, 250
Midwestern Prevention Project, 598, 599	coronary heart disease, 233, 351, 356
Mila Schön brand, promotions, 522	fetal, 290
Military women, 39	Parkinson's disease, 336
smokeless tobacco, 120	peptic ulcers, 324
smoking and body weight, 128	perinatal, 15, 370
Milwaukee Journal surveys, 26, 42	smoking intensity, 188–189
Mineral supplements, 291	smoking-related, 193
Minimal contact See Clinical interventions, minimal	temporal trends, 186–189
Minnesota Heart Health Program, 599	Mothers, self-help programs, 554
coronary heart disease, 588–589	Motor performance
gender and smoking cessation, 554	menstrual cycle, 560
health behavior, 473	nicotine effects, 341
smoking prevention, 599	Mouth cancer, 224–225
smoking reduction, 99	Ms. brand
Minnesota Heart Survey, black women, 579	appeal to women, 522
Minnesota Nursing Network for Tobacco Control, 601	targeting women, 526
Minnesota Smoking Prevention Program, 598	MTF See Monitoring the Future Surveys
Minority women, smoking cessation, 578–584, 606	Multiparity See Parity

Multiple births, stillbirth risk, 291	smoking cessation among young women, 110
Muscle, skeletal, nicotine metabolism, 339	smoking during pregnancy, 73
Musculoskeletal anomalies, 303	smoking prevalence among young women, 50
Myeloid leukemia, 13	young women, 49
Myeloma, multiple, 231	National Household Surveys on Drug Abuse,
Myocardial infarction, 232	cigarette brand preference, 69
oral contraceptives, 237	National Institute for Occupational Safety and
N.T	Health, 123
N	environmental tobacco smoke and lung cancer, 343 National Longitudinal Study of Adolescent Health,
N-acetyltransferase 2 genes, 216	334
N' -nitrosoanabasine, 204–205	National Maternal and Infant Health Survey, 71, 111
N' -nitrosoanatabine, $204–205$	National Natality Survey, 71
N -nitrosonornicotine, 203–205	National Organization of School Nurses, 601
Nasal spray, nicotine, 340	
Nass, 138	National Organization for Women, 601, 602, 603, 605
Naswar, 138	National Program of Health Survey, 71
NAT1 genes, 216	National Pregnancy and Health Survey, 71
NAT2 genes, 216	National Smoking Cessation Campaign for African
National Association of African Americans for	American Women, 602
Positive Imagery, 602	National Survey of Family Growth, 71, 272
National Association of Flight Attendants, 602	National Survey of Health and Development, 482
National Association of Public Health Policy, 601	National Teenage Tobacco Surveys, 23, 52, 54, 59
National Cancer Institute, 193	National Vital Statistics Systems, 257
community intervention programs, 589	National Youth Risk Behavior Survey See Youth Risk
Four A's protocol, 579–580	Behavior Survey
public health partnerships, 600	National Youth Tobacco Survey, 23, 52, 54–56, 67, 68, 69
	bidis, <i>121</i>
National Comorbidity Survey, smoking prevalence, 333 National Health Interview Surveys, 23, 257	cigars, 117–118
· ·	physician advice about smoking, 115
age at smoking initiation, 223	pipes, 119
Cancer Control Supplement, 550	smokeless tobacco, 121
risk taking behaviors, 472	smoking cessation, 95
smoking initiation, 499	Native American See under entries at American Indian
tobacco product pricing, 455	Nauru, See also Asian or Pacific Islander women
National Health and Nutrition Examination Survey	type 2 diabetes, 264
Epidemiologic Followup Study, 324, 486	Navajo girls, See also American Indian girls
National Health and Nutrition Examination	current smoking, 59
Survey I, weight gain, 309, 310	smokeless tobacco, 121
National Health and Nutrition Examination Survey III, 23	Navajo students, smoking prevention, 598
body mass index, 128	Navajo women, See also American Indian women, 40
environmental tobacco smoke, 123	Neonatal morbidity, 290
smoking and body weight, 128	Neonatal mortality, 290, 294-296; See also Perinatal
workplace exposure, 124	mortality
National Hospital Ambulatory Medical Care Survey, 257	environmental tobacco smoke, 364–365, 372
National Hospital Discharge Survey, 257, 258	Neoplasia, cervical intraepithelial, 220
National Household Surveys on Drug Abuse, 23, 46, 52	environmental tobacco smoke, 224
binge drinking, 130	Nervousness, 473
cigar use, 117	Netherlands
current smoking, 39	lung cancer mortality, 210–211
current smoking among girls, 56–63, 57, 58	smoking trends, 138
ever smoked, <i>33</i> , <i>53</i> , <i>54</i> , <i>595</i>	Neural tube defects, 303, 304
ever smoking by age, 78	environmental tobacco smoke, 366
frequent smoking, 62	Neurologic diseases, 15, 336–338, 372
high school drop outs, 66	Neuroticism, 482
nicotine dependence, 86, 88, 89, 91, 338, 556–557	Neurotransmitters, 570
other drug use, 129–130, 130	Never active smokers, breast cancer risk, 213, 216
smokeless tobacco use, 119	New Mexico, air pollution and lung cancer risk, 208
smoking among high school senior girls, 59	New Zealand
smoking cessation, 101	lung cancer trends, 210–211

smoking prevalence, 136	symptoms in girls, 93
smoking trends, 138	NIOSH See National Institute for Occupational
New Zealand, Toxic Substances Board, 525	Safety and Health
Newport brand, 46, 504	Nonsmokers
advertising, 498	chronic obstructive pulmonary disease, 259
preference among girls, 69, 70	congenital malformations, 366
sponsorship, 511	coronary heart disease, 351, 356, 372
NHANES See National Health and Nutrition	environmental tobacco smoke, 123
Examination Survey	hormone replacement therapy, 237
NHIS See National Health Interview Surveys	lung cancer, 197, 343, 372
NHSDA See National Household Surveys on Drug	lung function, 252
Abuse	maintaining status, 469
Nicotine, 83, 273, 303	risk of death, 12
antidepressive effects, 333	Norms, social, 469
birth weight, 364	North Africa, smoking prevalence, 136
breast fluid, 212	North Carolina, oral cancers, 225
cervical mucus, 223	North Karelia Youth Project, 588, 598
clearance, 339	Northwest Portland Area Indian Health Board, 602
congenital malformations, 304	Nortriptyline, 334, 556, 557, 570
effect on sex hormones, 269	Norway
hair samples, 364	bladder cancer, 229
hormones, 558	lung cancer, 210–211
inflammatory bowel disease, 325	pancreatic cancer, 228
low-nicotine content, 506	smoking prevalence, 136
osteoblasts, 318	NTTS See National Teenage Tobacco Surveys
pharmacology, 338–342, 372	Nulliparity See Parity
physical dependence, 342	Nurses, See also U.S. Nurses' Health Study
pyschoactive effects, 340–342	self-help programs, 554
reduced content, 97	weight gain and smoking cessation, 565
self medication 222	Nurses' Health Study See U.S. Nurses' Health Study
self-medication, 333	ruises Health Study See C.S. ruises Health Study
·	reach study See C.S. Ivaises Treath study
stillbirth, 294 tolerance, 342	ivaises Health Study See C.S. Ivaises Health Study
stillbirth, 294	O
stillbirth, 294 tolerance, 342 transdermal system, 342	0
stillbirth, 294 tolerance, 342	Obesity See Body weight
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372	Obesity See Body weight Obstructive airways disease See Chronic obstructive
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334	O Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606	O Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342 Nicotine metabolism, 552	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273 Oophorectomy, 269
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342 Nicotine metabolism, 552 gender differences, 476	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273 Oophorectomy, 269 Ophthalmopathy, in Graves' disease, 263
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342 Nicotine metabolism, 552 gender differences, 476 Nicotine nasal spray, 340, 556	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273 Oophorectomy, 269 Ophthalmopathy, in Graves' disease, 263 Oral cancer, 13, 116, 224–225, 369
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342 Nicotine metabolism, 552 gender differences, 476 Nicotine nasal spray, 340, 556 Nicotine patch, 556, 557	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273 Oophorectomy, 269 Ophthalmopathy, in Graves' disease, 263 Oral cancer, 13, 116, 224–225, 369 smokeless tobacco, 231
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342 Nicotine metabolism, 552 gender differences, 476 Nicotine nasal spray, 340, 556 Nicotine patch, 556, 557 pregnancy, 557	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273 Oophorectomy, 269 Ophthalmopathy, in Graves' disease, 263 Oral cancer, 13, 116, 224–225, 369 smokeless tobacco, 231 Oral clefts, 305
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342 Nicotine metabolism, 552 gender differences, 476 Nicotine nasal spray, 340, 556 Nicotine patch, 556, 557 pregnancy, 557 weight control, 568	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273 Oophorectomy, 269 Ophthalmopathy, in Graves' disease, 263 Oral cancer, 13, 116, 224–225, 369 smokeless tobacco, 231 Oral clefts, 305 environmental tobacco smoke, 366
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342 Nicotine metabolism, 552 gender differences, 476 Nicotine nasal spray, 340, 556 Nicotine patch, 556, 557 pregnancy, 557 weight control, 568 Nicotine replacement therapy, 98, 555, 556–557	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273 Oophorectomy, 269 Ophthalmopathy, in Graves' disease, 263 Oral cancer, 13, 116, 224–225, 369 smokeless tobacco, 231 Oral clefts, 305 environmental tobacco smoke, 366 Oral contraceptives
stillbirth, 294 tolerance, 342 transdermal system, 342 Nicotine dependence, 12, 16, 17, 82–93, 142, 334, 372 anxiety disorders, 334 gender, 91, 606 heavy smoking, 574 indicators, 86, 89 pharmacologic processes, 16, 478 pharmacotherapy, 556–558 smoking cessation, 552 teens, 74 treatment methods, 552–558 Nicotine gum, 342, 556, 584 weight control, 566, 567–568 Nicotine inhalers, 556 weight control, 568 Nicotine intake, 342 Nicotine metabolism, 552 gender differences, 476 Nicotine nasal spray, 340, 556 Nicotine patch, 556, 557 pregnancy, 557 weight control, 568 Nicotine replacement therapy, 98, 555, 556–557 depression, 333	Obesity See Body weight Obstructive airways disease See Chronic obstructive pulmonary disease Occupation lung cancer risk, 208 smoking status, 486 Occupational exposure, environmental tobacco smoke, 123 Occupational settings See Worksite smoking cessation programs Occupational status, 39, 576 Office on Smoking and Health, Centers for Disease Prevention and Control, 602 Old Gold brand, advertising, 494 Older smokers, cessation, 554 Ontario, Canada, air pollution and lung cancer risk, 208 Oocytes, 273 Oophorectomy, 269 Ophthalmopathy, in Graves' disease, 263 Oral cancer, 13, 116, 224–225, 369 smokeless tobacco, 231 Oral clefts, 305 environmental tobacco smoke, 366

coronary heart disease risk, 248	smoking status and smoking after pregnancy,
ectopic pregnancy, 277	483–485
heart disease risk, 13-14	Passive smoking See Environmental tobacco smoke
nicotine, 561–562	Paternal smoking
smoking cessation, 552	birth weight, 364
stroke, 241, 248, 370	congenital malformations, 366
stroke risk, 14	neonatal mortality, 365
thyroid cancer, 230	Pawtucket Heart Health Program, 589
Organisation for Economic Co-operation and	Peers, 67
Development, 597	attitudes toward smoking, 470
Oropharyngeal cancer, 231, 369	smoking initiation among adolescents, 469
Oslo Youth Study Smoking Prevention Program, 598	Pelvic inflammatory disease, 276, 278
Osteoarthritis, 15, 329, 330, 371	Peptic ulcers, 15, 324–325, 371
Osteoblasts, 318	Peribronciolar alveoli, inflammation, 249
Osteoporosis, 311, 317, 583	Perinatal mortality, 15, 290, 303, 307, 368, 370, 372; See also
Ovarian atresia, 219	Neonatal mortality
Ovarian cancer, 13, 219–220	environmental tobacco smoke, 16
risk, 223, 369	Periodontitis, 116
Ovarian cysts, 272	Peripheral vascular disease, 244
Ovarian function, 269	atherosclerosis, 14, 370
Ovarian pathology, 273	smoking cessation, 248
Ovulation frequency, cancer risk, 219	subclinical, 247
Oxford Family Planning Contraceptive Study, 321	Personal characteristics, 478
Oxiora Family Framing Contraceptive Study, 521	smoking initiation, 471
	Personal influences, 453
P	
r	Personality disorders, 131  Peter Stunyosopt brond brond stretching, 522
p53-Tumor-suppressor gene, 207	Peter Stuyvesant brand, brand stretching, 522
p53 Positive tumors, 216	Pharmacologic approaches
Pacific Islands, smoking prevalence, 136	smoking cessation, 556–558
Pack-years, 198	weight control, 567–569
carotid atherosclerosis, 241	Pharmacologic processes, 486–487
chronic obstructive pulmonary disease, 261	Pharyngeal cancer, 13, 224–225
coronary heart disease risk, 353	Phenylpropanolamine gum, 569
environmental tobacco smoke, 344, 353	Philip Morris, 490, 498
lung cancer, 201	advertising, 510, 520, 521, 524
menopause, 269	cigarette brand, 46
oocytes, 273	international sponsorship, 523
rheumatoid arthritis, 328	product placement, 523
Pall Mall brand, advertising, 498	promotions, 510
	sponsorship, 513–514
Pancreatic cancer, 13, 228, 231, 369	Physical activity, 486
Panic disorders, 131	Physician intervention, 554
Papillary thyroid cancer See Thyroid cancer	Physicians, advice about smoking, 112–115, 116
Parathyroid hormone, 318	Pima Indian women, See also American Indian
Parental, smoking, 468–469, 470	women
Parental education, smoking initiation, 471	type 2 diabetes, 264
Parental smoking, 252, 468–469, 470; See also	Pipes, 12, 118–119, 132
Maternal smoking	Placental abnormalities, 291
diabetes in children, 264	Placenta previa, 14–15, 281, 307, 370
Parents, smoking initiation, 455, 468–469	Plaque thickness, 243
Parity, 483	Players Navy Cut brand, 519
low birth weight, 296	Pneumonia, 252
placenta previa, 281	Polacrilex gum, 332, 556; See also Nicotine gum
preeclampsia, 288	Poland
smoking cessation, 579	air pollution and lung cancer risk, 209
stillbirth, 291	lung cancer, 209, 211
Parkinson's disease, 16, 338, 372	Policy, smoking cessation, 584–597
Parliament brand, advertising, 497, 509	Polycyclic aromatic hydrocarbons, 219, 269, 273
Partner See also Spouse	Polymorphism. 476

Population attributable risk, 190	Project SMART, 598
Portugal	Project Towards No Tobacco Use, 598
lung cancer, 209, 211	Prolactin, 306
smoking prevalence, 136	Promotions, 490, 491–492, 509–511
smoking trends, 138	restrictions, 524–526
Postpartum period, 564	Proteinuria, 283, 288
relapse to smoking, 487, 555	Proximal duodenum, 324
Poverty, 575; See also Income level	Proximal humerus, fractures, 319
smoking cessation, 101	Proximal influences, 453
smoking prevalence, 42	Prozac See Fluoxetine hydrochloride
Predictor variables, 479	Psychiatric disorders, 15–16, 131, 333–336, 371
Predictors, smoking cessation, 483	Psychological disturbances, 473
Preeclampsia, 15, 283, 288, 307, 370	Psychosocial problems and smoking, 134
Pregnancy, 8, 12, 71–73, 142	Psychosocial resources, smoking after pregnancy, 484
adverse outcomes, 288	Psychosocial variables, smoking cessation, 552
bleeding during, 278	Public attitudes, 592
diabetes in children, 264	Public health initiatives, 599–600
ectopic, 276, 277–278, 307, 370	Public Health Service Update (2000), 555
estriol levels, 262	Public health settings, smoking cessation, 576
estrogen levels, 262	Public transportation, 521
gallstones, 321	Pueblo students, See also American Indian girls
maternal smoking and infant lung development, 251	smoking prevention, 598
nausea and vomiting, 561	Puerto Rican American girls
nicotine replacement therapy, 557	smoking intensity, 62
prenatal smoking, 484	smoking prevalence, 61
self-help programs, 554	Puerto Rican American women, 39
smoking, 71–73	cigarette brand preference, 47
smoking cessation, 17, 111–112, 483–485, 552, 555,	environmental tobacco smoke, 122
562-564, 606	heavy smokers, 45
smoking cessation among black women, 579-580	smoking during pregnancy, 73
smoking cessation among low income women, 575	smoking prevalence, 29
smoking prevalence, 73	Puff volume, 330
smoking reduction, 602	
socioeconomic status and smoking cessation,	
577–578	$\mathbf{Q}$
Pregnancy rates, 273	Ovenerhou Chine environmental teheses emake
Pregnancy Risk Assessment Monitoring System, 73	Quangzhou, China, environmental tobacco smoke
Premature rupture of membranes, 290	exposure, 345
Premenstrual distress, smoking cessation, 560	Quit ratio, 100
Premenstrual dysphoric disorder, 561	Quit Victoria, 604
Premenstruum	Quitting smoking See Smoking cessation
nicotine intake, 559	
withdrawal symptoms during, 560	D
Prenatal smoking, 484	R
Press See Media	Race
Preterm delivery See Delivery, preterm	age at smoking initiation, 76
Preterm premature rupture of membranes, <i>14</i> , <i>15</i> , <i>278–279</i> , <i>307</i> , <i>370</i> , <i>371</i>	birth weight, 302
	cigarette brand preference, 70
Prevalence See Smoking prevalence	lung cancer, 200
Price, tobacco, 510	preeclampsia, 288
Print media, 521	relapse to smoking, 487
Product packs sing. 402	smoking among girls, 60, 61
Product packaging, 492–493	smoking prevalence, 57, 73
Product placement, 523	spontaneous abortion, 281
Progestins, 236, 262	stillbirth, 291
Progestogen, 217	Radiation
Project ALERT, 598	congenital malformations, 303
Project SHOUT, 598	ionizing, 209

thyroid cancer, 230	Romania, lung cancer mortality, 211
Radio, 521	Rompa con el Vicio: Una Guía Para Dejar De Fumar, 582
Radius, <i>312</i>	Rural population, smoking cessation among blacks,
Radon, 207	581
lung cancer, 209	
Rancho Bernardo Heart and Chronic Disease Study,	
253	S
Ranitidine, 324	C-C-QWl
Rate difference, smoking status and mortality, 186	Safe@Work coalition, 513
Rebelliousness, smoking initiation among	Saint Laurent, Yves, 506; See also Yves Saint Laurent
adolescents, 472	brand
Receptors, D <sub>2</sub> dopamine, 476	Salem brand, 46, 47
Reducing Tobacco Use, 556	advertising, 506
Reemtsma R1 Minima brand, appeal to women, 522	international sponsorship, 523
Refusal skills, 474	Salivary gland tumors, 225
Regent brand, advertising, 496	SAMMEC See Smoking Attributable Mortality, Morbidity, and Economic Costs
Reinforcers, conditioned, 342	Satin brand, 506
Relapse to smoking See Smoking, relapse to	Schizophrenia, 16, 131, 335, 336, 371
Relative risk, defined, 184	School grade, 56
Relaxation, smoking, 473	current smoking, 58, 59
Religion, 66, 67, 71	School-based interventions, 597–598
Religiousness, 473	Schools
Renal cell cancer, 228	smoking cessation programs, 572
Renal parenchyma, 228	smoking initiation, 472
Renal pelvis cancer, 228	smoking restrictions, 593
Report on Carcinogens, 344	Scotland, lung cancer in women, 210
Reproduction	Seizures, 288
assisted, 273	Selenium, 208
environmental tobacco smoke, 343	Self-efficacy, 470, 483, 488
Reproductive age, smoking prevalence, 35–36	Self-esteem, 473
Reproductive history, smoking, 219	Self-help programs, 553–554, 564, 581
Reproductive outcomes, 14, 272–307, 370–371	black women, 579
and environmental tobacco smoke, 16 environmental tobacco smoke, 356–368, 372	Self-image, 490
Research, 636	tobacco advertising, 504
smoking prevention, 597–600	Self-medication, 15, 333, 336, 340
Respiratory anomalies, 303	smoking and depression, 471
Respiratory tract, lower, 252	Self-report, smoking during pregnancy, 563
Restaurants, smoking restrictions, 593	Sensation seeking, 472
Restlessness, and smoking, 134	Sensory cues, 342
Retinol, 208	Sensory motivation, 482
Rheumatoid arthritis, 15, 327-329, 330	Sensory performance, nicotine effects, 341
Risk behavior syndrome, 472	Sex hormone-binding globulin, 218
Risk factors	body fat distribution, 311
other than smoking, 189–190	Sex hormones, 14, 230, 262–263, 370
postpartum relapse, 564	effects of nicotine, 269
Ritz brand, 506	oxidase systems, 217
R.J. Reynolds, 490, 506, 508	Sexual behavior, 223
advertising, 510	Sexual intercourse, smoking and cervical cancer, 220
counteradvertising, 603	Sexually transmitted diseases, 223, 277, 331
international sponsorship, 523	Shenyang, China, air pollution and lung cancer risk,
promotions, 510	208
sponsorship, 511, 513–514	Sibling smoking, smoking initiation among
RJR Nabisco <i>See</i> R.J. Reynolds	adolescents, 469
Robert Wood Johnson Foundation	Silk Cut brand, brand stretching, 522
cigar use, 118	Silver acetate, 556
community intervention programs, 589	Singapore, smoking prevalence, 136
Robert Wood Johnson Youth Access Survey, 595	Single photon absorptiometry, 312

Skeleton, axial, 312	antiestrogenic effects, 217, 230, 262
SLC6A3-9, 476	aortic atherosclerosis, 247, 248
Sleeping position, infant, 306	birth cohorts, 27
Smoke See Environmental tobacco smoke; Tobacco	blood pressure, 247, 248
smoke	body weight, 125–128
Smoke inhalation	breast cancer, 212-217, 224
aortic aneurysm, 247	calming effects, 85
cancer risk, 202	cervical cancer, 220–224
cervical cancer, 220	combined with alcohol, 224-225, 226
Smoke-free policies, 123–124	coronary heart disease, 232-238
SmokeFree Kids & Soccer Campaign, 600	current, 34–42
SmokeLess States program, 589	daily See Smoking, current
Smokeless tobacco, 12, 116, 142	depression risk, 334
cessation programs, 549–550	disease outcomes, 634
international use, 138–139	endometrial cancer risk, 224
marketing, <i>516–517</i>	escalation to, 454
oral cancer, 225, 231	esophageal cancer, 226
prevalence, 122	experimental, 67, 474; See also Smoking initiation
use by women, 119–121	frequent, <i>62</i>
Smokers, current	goiter, <i>263</i>
benign breast disease, 217	heavy See Smoking intensity
breast cancer, 212, 215	impact on women's health, 633
cervical cancer, 223	insulin resistance, 265
chronic obstructive pulmonary disease, 259	laryngeal cancer, 225–226
dysmenorrhea, 266	lung cancer, 209
endometrial cancer, 369	oral cancer risk, 225
gestational diabetes, 265	oral contraceptives, 236–237
hip fractures, 318	oropharyngeal cancers, 224–225
inflammatory bowel disease, 325	ovarian cancer, 219–220, 224
intermittent smoking, 100	perceived norms, 469
lung function, 250, 252	peripheral vascular disease, 244–247
<del>-</del>	
mental illness, 333	pharyngeal cancer risk, 224–225
peripheral vascular disease, 247	relapse to, 485, 487–488, 551–552
risk of death, <i>12</i> stroke risk, <i>240</i>	relaxing effects, <i>85</i> stomach cancer, <i>226</i>
ulcerative colitis, 371	transition from, 479–487
weight gain, 565	trends, 34–39
Smokers, former	type 2 diabetes risk, 264
benign breast disease, 217	uterine fibroids, 271–272
body weight, 311	vulvar cancer risk, 224
breast cancer risk, 212	young women, 49–51
chronic obstructive pulmonary disease, 250, 261, 370	Smoking abstinence
diabetes risk, 264	chronic obstructive pulmonary disease, 250
dysmenorrhea, 266	coronary heart disease risk, 233
endometrial cancer, 369	lung function, 252
facial wrinkling, 332	stroke risk, 248
gestational diabetes, 265	Smoking, age at initiation
hip fracture, 318	breast cancer risk, 213
infertility, 273–276	coronary heart disease, 233, 233
inflammatory bowel disease, 325	Smoking Attributable Mortality, Morbidity, and
lung cancer risk, 13, 200, 209, 369	Economic Costs, 190
lung function, 252	Smoking behavior, research, 635
spontaneous abortion, 282	Smoking cessation 8, 12, 17, 115, 142, 477–488; See also
stroke risk, 230	Smoking reduction
ulcerative colitis, 325	abruptio placentae, 281
Smoking	adolescent girls, 572–573
acute myeloid leukemia, <i>231</i>	adults, 485–486
age at initiation, 12	age groups, 482–487

alcohol consumption, 485	Smoking Cessation, Clinical Practice Guideline, Agency
antidepressive drug treatment, 334, 336	for Health Care Policy and Research, 555
attempts, 16, 93-99, 96, 479, 485	Smoking continuum, 115
birth weight, 303	ever smoking, 107-109
body weight, 125, 309-310	Smoking duration
bone density, 315	aortic aneurysm risk, 247
carotid atherosclerosis, 248, 370	chronic obstructive pulmonary disease, 370
chronic obstructive pulmonary disease, 250, 253, 261	coronary heart disease, 232
community studies, 588–590	lung cancer, 202
conception delay, 307	lung cancer risk, 198
coronary heart disease, 233, 248, 369	mortality, 193, 368
demographic characteristics, 101-102	Smoking initiation, 74–82
depression, 333, 372	age at, 198
duration of abstinence, 488	among adolescents, 63
economic benefits, 564	biological factors, 476–477
gender, 102–106, 551	birth cohorts, 77–81
girls, 86, 95–96	body weight, 308
infertility, 307	cigarette price, 454–455
innovations, 550	decision to smoke, 455
issues for women, 558-564	environmental factors, 453-470
liver cancer risk, 228	influencing factors, 454-477
low birth weight, 307	lung cancer, 198
lung cancer risk, 369	mood, 476
lung function, 262, 370	other drug use, 130, 134
mass media approach, 576–577	perceived approval, 470
menstrual cycle, 560–561	personal factors, 475–476
methods, 17, 96–99, 116, 549–558	predictors, 454, 527
mood disorders, 372	prevention, 549
neonatal mortality, 295	rate, <i>81–82</i>
nicotine dependence, 88	smoking duration risk, 198
nicotine dependence treatment methods, 552–558	social factors, 454–470
older adults, 486-487, 562	stages, 474
older women, 583	tobacco marketing, 498–505, 527
overweight women, 127	Smoking intensity 12, 13, 62-63, 193, 372; See also
peptic ulcers, 324	Cigarettes, number smoked; Dose-response
peripheral vascular disease, 244, 370	relationship
pharmacological treatments, 636	abruptio placentae, 281
predictive variables, 86, 487	all-cause death rates, 186
predictors, 485, 488, 527, 553	among girls, 70
pregnancy, 15, 111–112, 471, 483–485, 562–564	birth weight, 303
premature death risk, 368	body weight, 308
preterm delivery, 291, 307	breastfeeding, 306
preterm premature rupture of membranes, 279, 307	chronic bronchitis, 250
programmatic and policy approaches, 584-597	chronic obstructive pulmonary disease, 13, 261, 370
psychiatric disorders, 16	coronary heart disease, 233, 233
psychosocial predictors, 482	diabetes mellitus, 264
public health settings, 576	dysmenorrhea, 266
reasons, 106	environmental tobacco smoke, 344, 353
research, 635	fertility, 276
stages, 109-110	gallstones, 321
stroke, 248	heavy, 42-46, 48, 574
stroke risk, 240, 370	hip fracture, 318
study population, 479	human immunodeficiency virus, 331
trends, 100–101	human papillomavirus, 223
unassisted, 552-553, 574	intermittent, 42, 100
weight gain, 309, 311, 431, 371	liver cancer, 227–228
worksite activities, 584–585	low birth weight, 302
young persons, 482-483	lung cancer, 197, 198, 200, 368

macular degeneration, 330	Social reality, 491
mortality risk, 188–189, 368	Social strata, 486
nicotine dependence, 88, 89, 142, 372	Social support, 570-572
nicotine exposure, 340	smoking cessation, 488, 527
osteoarthritis, 329	Sociodemographic factors, 65–66, 71
ovarian cancer, 219	Socioeconomic status, 575–576
pancreatic cancer, 228	cessation activities at work, 578
pregnancy, 563	lung development, 251
pregnant women, 73	relationship to smoking, 63-67
preterm delivery, 290	smoking cessation, 575
smoking cessation, 86, 100, 482, 485, 486, 488, 527	smoking initiation among adolescents, 471
stroke risk, 240	Somatostatin, 265
trends, 42–46	South Africa
women and smoking cessation, 573	smokeless tobacco use, 139
Smoking intention, 470	smoking prevalence, 136
Smoking maintenance, 477–488	South African women, smoking prevalence, 136
study populations, 479	South American women, smoking during pregnancy, 73
Smoking policies, 17	Southwest Cardiovascular Curriculum Project, 598
restrictive, 585–586, 587, 592	Spain
Smoking, pregnancy, 564	lung cancer, 211
Smoking prevalence, 7, 11, 28–29, 39–42, 48	smoking prevalence, 136
among high school senior girls, 60	smoking trends, 138
among men, 29	Special Lights brand, international sponsorship, 523
during pregnancy, 73	Sperm, environmental tobacco smoke, 366
ethnicity, 635	Spina bifida See Neural tube defects
international patterns, 135–139	Spine, <i>312</i>
international trends, 12, 138, 142	Spirometry, 249, 253
lung cancer, 203	Sponsorship, 490, 492, 511–515, 633
mental illness, 333	counteractivities, 604–605
perceived norms, 469	international, 522–523
race, <i>635</i>	restrictions, 515
sexual orientation, 635	women's tennis, 604–605
socioeconomic status, 635	Sporting events, sponsorship, 492
Smoking prevention, 597–600, 606	Spousal smoking, 350
research, 635	coronary heart disease, 353, 372
Smoking reduction, 8, 12, 11	delayed conception, 366
Smoking reduction, 17, 86, 88, 97, 99, 636; See also Smok-	environmental tobacco smoke, 356
ing cessation	Spouse
Smoking, relapse to, 107, 551, 552	environmental tobacco smoke, 343, 344
body weight, 125	smoking after pregnancy, 485
menstrual cycle, 560–561	Spud brand, advertising, 494
mental health, 131	Squamous intraepithelial neoplasms, 220
postpartum period, 564	Stages-of-change model, 109–110, 478
pregnancy, 563–564	Stanford Five-City Project, 36, 588–589
Smoking status	smoking intensity, 45
attitudes, 67	Stanford Three-Community Study, 588
benign breast disease, 217	Stillbirth, 15, 291–294, 304, 307, 370
Smoking trends, 138	environmental tobacco smoke, 364
historical, 23–28	Stimulation, nicotine, 341
Sociability, smoking initiation among adolescents, 471	Stomach cancer, 13, 226, 231, 369
Social acceptability, 521	Strategic Coalition of Girls and Women United Against
Social bonding, relationship to smoking, 63	Tobacco, 601, 605
Social class, spontaneous abortion, 281	Stress, 473, 557
Social desirability of smoking, 67	nicotine, 341
Social factors, 453, 478	Stress reduction, 569
smoking cessation, 551	smoking, 473
smoking tessation, 331 smoking initiation, 454–470	Stroke, 14, 232, 238–241, 369
Social network, pregnancy and smoking cessation, 484	hemorrhagic, 240
DUCIGI HELWOLK, PLESHALICY ALIU SHIUKHIS CESSAUUH, 404	nomornagio, att

ischemic, 240	ever smoked, 54
risk, 248	first cigarette of the day, 84
Students, restrictive smoking policies, 593	nicotine dependence indicators, 91
Study of Osteoporotic Fractures, 315	nicotine withdrawal, 88–89, 91, 93
Style brand, 508	reasons for smoking, 85
Subarachnoid hemorrhage, 14, 369	smokeless tobacco, 121
oral contraceptives, 241	smoking cessation among girls, 111
risk, 240, 248	weekly income, 66
Substance abuse, adolescents, 573	Television, 521
Sudden infant death syndrome, 15, 290, 306–307, 370	Temporal trends, smoking-associated risks, 202–203
Sun exposure, 332	Tennis, tobacco company sponsorship, 511, 604–605
Survey of American Indians and Alaska Natives of the	Tennis Legends Tour, 604
National Medical Expenditure Survey (1987), 40	Testosterone
Surveys, public tobacco-related attitudes, 592	body fat distribution, 311
Survival rates, lung cancer, 195	maternal levels, 477
Susceptibility to smoking, 474	metabolism, 262–263
Sweden	Tetralogy of Fallot, environmental tobacco smoke, 366
beauty pageant, 606	Thailand, smoking prevalence, 136
bladder cancer, 229	Thiocyanate, 263
lung cancer mortality, 210–211	levels during pregnancy, 563
pancreatic cancer, 228	Throat irritation, 494, 495, 498
smokeless tobacco use, 138	Thyroid cancer, 13, 230–231, 369
smoking trends, 138	Thyroid disorders, 74, 263–264, 370
Swedish National Institute of Public Health, 606	Thyroid hormones, 74, 263, 265, 370
Swedish Nurses Against Tobacco, 601	Thyroid nodules, 230
Switzerland, lung cancer mortality, 210–211	Thyroid volume, 263
Systemic lupus erythematosus, 15, 329–330, 371	Thyroid-stimulating hormone, 230, 263
	Thyroiditis, autoimmune, 263
	Thyrotoxicosis, 230
T	Thyroxine, 263
	Tobacco company sponsorship See Sponsorship
Take Heart project, 586	Tobacco control, women's leadership, 605-606
TAPS I See Teenage Attitudes and Practices Survey I	Tobacco control advocacy programs, 600-606
TAPS II See Teenage Attitudes and Practices Survey II	Tobacco control programs, 636
Tar content	Tobacco industry, 8
adenocarcinoma, 203	marketing, 16–17
low, 48, 97, 506	promotion, 524
lung cancer risk, 200	targeted advertising, 633-634
Tareyton brand, advertising, 494	Tobacco Institute, sponsorship, 514
Task Force on Women & Girls, Tobacco & Lung	Tobacco Institute, sponsorship, 514  Tobacco Institute in Japan, advertising restrictions, 525
Cancer, 601	Tobacco prevention strategies, 600
Taxation policies, 594–595	Tobacco products
Tecumseh Community Health Study	accessibility, 454
coronary heart disease, 232	· ·
type 2 diabetes, 264	advertising and promotion, 455
Teenage Attitudes and Practices Survey I, 23, 52	price, 510
body weight, 126	sales to minors, 454
cigarette brand preference, 70, 500	Tobacco settlement See Master Settlement Agreement
depression in girls, 134	Tobacco smoke, 273; See also Environmental tobacco
emotions, 134	smoke
ever smoked, 55	exposure and gender, 202
smokeless tobacco, 121	inhaled, 198
	lung cancer histology, 201–202
smoking cessation among girls, 111	Tobacco Society for Voice Culture, 494
smoking cessation attempts, 95	Tobacco use, 16
weekly income, 66	patterns, 11–12
Teenage Attitudes and Practices Survey II, 23, 52	twin studies, 476
cigarette brand preference, 69, 500	Tobacco-related policies, 591-597
depression in girls, 134	Tobacco-specific nitrosamines, 203–205, 635
emotions, 134	•

Toluene, neonatal mortality, 365	gallstones, 322
Tongue cancer, 225	menopause, 269
Tooth loss, 110	mortality risk, 189
Transdermal nicotine patch See Nicotine patch	pancreatic cancer, 228
Transforming growth factor alpha, 305, 366	polymorphism and breast cancer, 216
Transient ischemic attack, hormone replacement therapy,	rheumatoid arthritis, 327
241	smoking cessation, 485, 487
Transtheoretical model of change, 474, 478	systemic lupus erythematosus, 330
Treatment approaches, older women, 583–584	type 2 diabetes, 264
Trends See Smoking trends	weight gain, 310
Triiodothyronine, 263	U.S. Women's National Soccer team, 600
TSNAs See Tobacco-specific nitrosamines	Uterine fibroids, 14, 271–272, 370
Tucson Epidemiologic Study of Obstructive Lung Diseases, 249, 252	Uteroplalcental circulation, 303
Tucson Epidemiological Study of Airways	
Obstructive Disease, 253	$\mathbf{V}$
Tumor-suppressor genes, 216	Visitables demondent ACA
Twin studies	Variables, dependent, 454
bone density, 315	Vascular disruption, congenital malformations, 304
gallstones, 322	Vasoconstriction, fetal growth retardation, 364
peptic ulcers, 324	Vegetable intake, 486
rheumatoid arthritis, 328	Vertebral fractures, 319
tobacco use, 476	Victorian Smoking and Health Program, 604
Type 1 diabetes See Diabetes mellitus	Video, 521
Type 2 diabetes See Diabetes mellitus	Vietnamese women, Seealso Asian or Pacific Islander women
	lung cancer incidence, 195
	Virginia Slims brand, 504–506, 508
U	advertising, 510, 521, 525
Till to the discount of the di	appeal to women, 522
Ultimate influences, 453	nitrosamine content, 203, 205
Underreporting, 53, 58	promotions, 509
smoking during pregnancy, 73	sponsorship, 511
Unemployment, 486	tennis tournament, 604
United Kingdom	Vitamin A, 208
advertising, 519	Vitamin C, 208
counteradvertising, 603	cervical cancer, 223
lung cancer, 209, 210–211	Vitamin E, 208
smoking trends, 138	Vitamin supplements, 291
United States	Vlagtwedde-Vlaardingen study, 253
lung cancer in developed countries, 209–211	Vogue brand, appeal to women, 521
smoking trends, 138	Vulvar cancer, 13, 224, 369
United States Tobacco Company, 490	
Uranium miners, lung cancer, 209	**/
Urinary tract cancers, 228–230	W
Urinary tract malformations, 305–306	WAGAT See Women And Girls Against Tobacco
Urogenital malformations, 303, 305–306	Waist-to-hip ratio, 310, 315
U.S. Department of Defense survey, smokeless	Wales, lung cancer, 210
tobacco, 120	Walnut Creek Study, coronary heart disease, 232
U.S. Environmental Protection Agency, 122	Waterloo Smoking Prevention Project, 598
U.S. Food and Drug Administration, Drug Abuse Advisry	Weight See Body weight
Committee, 99	Weight control, 475, 488, 527, 565–569
U.S. Nurses' Health Study	cigarette advertising, 494
body weight, 308	smoking initiation, 16
cataract, 330	Weight gain, 15, 309, 311, 551, 565, 606
cerebral hemorrhage, 240	
coronary heart disease, 232, 233, 234, 353	pregnancy, 288 smoking cessation, 17, 486
duration of smoking, 188–189	
environmental tobacco smoke, 353	Weight loss, 15, 134, 311, 371 Well being, 333
ever smoking by age, 78	Well-being, 333

Western countries See Developed countries	myocardial infarction, 237
Wheezing, 251, 252	WHO MONICAsurvey, smoking prevalence, 136
White adolescents	Winston brand, 46, 47, 504
emotional distress, 473	sponsorship, 514
risk taking behavior, 472	Withdrawal symptoms, 86, 88, 557
smoking prevalence, 635	gender differences, 476
weight control, 475	menstrual cycle, 559–560
White boys, smoking prevalence, 61	pharmacology, 557
White girls	Women, See under entries at Alaska Native,
cigarette brand preference, 70	American Indian, Asian or Pacific Islander, Black,
current smoking, 58	Canadian Indian, Chinese, Cuban American,
ever smoked, <i>55</i> , <i>56</i> , <i>59</i>	Filipino, Hispanic, Hopi, Japanese; entries at
physician advice about smoking, 115	Korean, Maori, Military, Navajo, Puerto Rican
smoking intensity, <i>62–63</i>	American, South African, and White
smoking prevalence, 7, 11–12, 57, 60, 67, 70, 142	Women And Girls Against Tobacco, 603, 604, 605
weight control, 476	Women Talk to Women About Smoking, 602
White men	Women United Against Tobacco Workshop, 605
chronic obstructive pulmonary disease mortality,	Women vs. Smoking Network, 603
260	Women's Action on Smoking, 526
lung cancer incidence, 194	Women's Health Equity Act, 514
smoking cessation, 106	Women's Health Initiative, 237, 562
smoking prevalence, 29	Women's magazine projects, 603-604
White women	Women's magazines See Magazines
age at smoking initiation, 74, 76, 77, 80	Women's organizations
birth weight, 302	tobacco control advocacy programs, 601-602
body mass index, 128	tobacco sponsorship, 511, 513
body weight, 127	Working Well Trial, <i>586–587</i> , <i>593</i>
bone fractures, 311	Workplace
chronic obstructive pulmonary disease mortality, 260	environmental tobacco smoke, 123-125, 350, 353
cigarette brand preference, 46	pregnancy and smoking cessation, 484
coronary heart disease risk, 232	Workplace exposure
current smoking, 39	coronary heart disease, 353
environmental tobacco smoke, 123	low birth weight, 362
ever smoking, 33, 78	Worksite
facial wrinkling, 332	smoking cessation, 578
first cigarette of the day, 83	smoking restriction policies, 593
heavy smokers, 43, 45, 46	Worksite smoking cessation programs, 575, 584–587
hip fracture risk, 318	efficacy, 586–587
lung cancer, 193, 197, 200	World Conference on Smoking and Health, 605
neonatal mortality, 294	World Conference on Tobacco OR Health, 600, 605
nicotine dependence, 88	World Health Organization, 605, 637
pregnancy and smoking cessation, 483, 577	Collaborative Study, 237
relapse to smoking, 487	MONICA survey, 136
smokeless tobacco, 119	Regional Office for the Western Pacific, 525
smoking cessation, 97, 100, 101, 105, 110	SmokeFree Soccer campaign, 600
smoking cessation during pregnancy, 111, 484	World Smoking and Health, 602
smoking continuum, 107	Wrinkling See Facial wrinkling
smoking during pregnancy, 71, 73	William & See Fucial William &
smoking initiation rate, 82	
smoking prevalence, 11, 28–29, 35, 48, 142	Y
stillbirth, 297	1
White young men, ever smoking, 49	Years of potential life lost, 190–191
White young women	U.S. women, 193
	Young adults
current smoking, $49$ ever smoking, $49$	attitudes about smoking, 67
	smoking cessation, 485–486
smoking prayalance 50	smoking initiation rates, 82
smoking prevalence, 50 WHO Collaborative Study, oral contracentives and	Young men
WHO Collaborative Study, oral contraceptives and	ever smoking, 49

sexual orientation, 59 smoking initiation, 82, 500 smoking prevalence, 51 Young women, See also under entries at Alaska Native, American Indian, Asian or Pacific Islander, Black, Chinese, Filipino, Hispanic, Japanese, Korean, and White cigarette smoking, 48-51 current smoking, 49-51 drug use, 129-130 first cigarette of the day, 83-85 nicotine dependence, 89, 91 other drug use, 130 physician advice about smoking, 115 reasons for cigarette use, 86 sexual orientation, 59 smoking cessation, 110-111 smoking initiation by age, 80 Young Women's Christian Association, 601 Youth See Adolescents Youth, bisexual, 59 Youth Access Survey, 595 Youth Risk Behavior Survey, 23, 52, 129-130, 472 binge drinking, 130 body weight, 125-126

cigar use, 118
current smoking, 57
ever smoked, 54, 56
frequent smoking, 63
sexual orientation, 59
smokeless tobacco, 121
smoking cessation attempts, 95–96
smoking initiation rates, 82
YPLL See Years of potential life lost
YRBS See Youth Risk Behavior Survey
Yves Saint Laurent brand See also Saint Laurent, Yves appeal to women, 522
international advertising, 520

## Z

Zinc, maternal levels, *278* Zyban *See* Bupropion